USPTO Patent Granted for HER4 Antibodies

ChangeBridge: Patent Grants - Pharma (A61K)

Published March 17th, 2026

Detected March 22nd, 2026

Summary

The USPTO has granted patent US12577324B2 to INSERM for antibodies with specificity to HER4 and their uses. The patent covers fully human anti-HER4 single-chain variable antibody fragments (scFv) that bind to an epitope of the HER4 protein.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12577324B2, titled "Antibodies having specificity to HER4 and uses thereof," to INSERM. This patent covers novel fully human anti-HER4 single-chain variable antibody fragments (scFv) that bind to specific epitopes on the HER4 protein, potentially enabling new therapeutic strategies. The patent was filed on December 8, 2020, and granted on March 17, 2026, with 16 claims.

This patent grant is primarily an intellectual property event and does not impose new direct compliance obligations on regulated entities. However, it signifies a new exclusive right for the assignee, INSERM, in the field of HER4 antibodies. Companies involved in the research, development, or commercialization of HER4-targeted therapies should review this patent to ensure their activities do not infringe on the granted claims. The patent's scope relates to specific antibody fragments and their uses, particularly in cancer treatment (A61P 35/00) and potentially other areas like reproductive health (A61P 15/00).

What to do next

Review patent US12577324B2 for potential infringement risks related to HER4 antibody development or use.

Source document (simplified)

← USPTO Patent Grants

Antibodies having specificity to HER4 and uses thereof

Grant US12577324B2 Kind: B2 Mar 17, 2026

Assignee

INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Inventors

Andre Pelegrin, Pierre Martineau, Thierry Chardes, Romain Lanotte

Abstract

The present invention relates to antibodies having specificity to HER4 and uses thereof, which are able to induce biased 4ICD routing/signaling. The inventors have isolated by antibody phage display three fully human anti-HER4 single-chain variable antibody fragment (scFv), selected on human HER4 extracellular domain, referred as C6 mAb, D5 mAb and F4 mAb and one fully human anti-HER4 scFv named H2 mAb, selected on NRG 1β1-stimulated EGFR/HER4 JMaCYT1-transfected NIH3T3 cells. In particular, the present invention relates to an isolated anti-HER4 antibody, wherein said antibody binds to an epitope of the HER4 protein.

CPC Classifications

A61K 47/6817 A61K 47/6869 A61K 2039/505 A61P 15/00 A61P 35/00 C07K 16/32 C07K 2317/21 C07K 2317/24 C07K 2317/565 C07K 2317/622 C07K 2317/73 C07K 2317/75 C07K 2317/76